BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30105947)

  • 1. Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
    Beckham TH; Romesser PB; Groen AH; Sabol C; Shaha AR; Sabra M; Brinkman T; Spielsinger D; McBride S; Tsai CJ; Riaz N; Tuttle RM; Fagin JA; Sherman EJ; Wong RJ; Lee NY
    Thyroid; 2018 Sep; 28(9):1180-1189. PubMed ID: 30105947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
    Romesser PB; Sherman EJ; Whiting K; Ho ML; Shaha AR; Sabra MM; Riaz N; Waldenberg TE; Sabol CR; Ganly I; McBride SM; Fagin JA; Zhang Z; Tuttle RM; Wong RJ; Lee NY
    Cancer; 2021 Nov; 127(22):4161-4170. PubMed ID: 34293201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
    Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
    Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.
    Romesser PB; Sherman EJ; Shaha AR; Lian M; Wong RJ; Sabra M; Rao SS; Fagin JA; Tuttle RM; Lee NY
    J Surg Oncol; 2014 Sep; 110(4):375-82. PubMed ID: 24961938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer.
    Freilich J; Hoffe SE; Almhanna K; Dinwoodie W; Yue B; Fulp W; Meredith KL; Shridhar R
    Dis Esophagus; 2015; 28(4):352-7. PubMed ID: 24635657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience.
    Cosper PF; Olsen J; DeWees T; Van Tine BA; Hawkins W; Michalski J; Zoberi I
    Radiat Oncol; 2017 Dec; 12(1):198. PubMed ID: 29216884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
    Lee NY; O'Meara W; Chan K; Della-Bianca C; Mechalakos JG; Zhung J; Wolden SL; Narayana A; Kraus D; Shah JP; Pfister DG
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):459-68. PubMed ID: 17493769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
    Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
    J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
    Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
    BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.